OakChart

OmniAb Inc

OABIHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:13 AM ET

5.07-0.03 (-0.59%)
2026-11-11 16:13 CET
Market cap
743.89 USD m
Revenue, TTM
40.21 USD m
Net income, TTM
-43.47 USD m
Free cash flow, TTM
2.38 USD m
EPS diluted, TTM
-0.34
P/E
-
Compare

Price

OABI against its 20, 50 and 200-day averages
2050200beat
2.003.004.005.009.2M18.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OABIclose 5.0720-day 4.9650-day 4.74200-day 2.835.07

7.0% under 5.45 on 9 Nov 2026. Last 15 sessions, 25.3% high to low

Profile

OABI
52-week range, 91% of the way up
1.355.45

OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

IndexRUT
Employees89
IPOSep 30, 2021
Beta0.60
ATR, 14d0.36
Rel volume0.35
Short float6.73%
Insider own18.49%
Inst own48.86%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap739.51M
Enterprise Value693.44M
Income-43.47M
Sales40.21M
Book/sh1.71
Cash/sh0.44
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees89
IPOSep 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S18.39
P/B2.97
P/C11.52
P/FCF310.72
EV/EBITDA-
EV/Sales17.25
Quick Ratio4.15
Current Ratio4.21
Debt/Eq0.07
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.34
EPS next Y-0.26
EPS next Q-0.12
EPS this Y39.35%
EPS next Y26.24%
EPS next 5Y49.14%
EPS past 3/5Y-29.62% -14.88%
Sales past 3/5Y-31.89% -14.39%
EPS Y/Y TTM42.74%
Sales Y/Y TTM90.63%
EPS Q/Q15.56%
Sales Q/Q78.34%
EarningsOct 30 BMO
EPS/Sales Surpr.5.59% 14.34%

Ownership

Insider Own18.49%
Insider Trans0.00%
Inst Own48.86%
Inst Trans-4.56%
ROA-14.48%
ROE-16.51%
ROIC-16.51%
Gross Margin39.60%
Oper. Margin-115.50%
Profit Margin-108.11%
SMA202.15%
SMA506.94%
SMA20079.27%
Trades-

Technical

Shs Outstand145.86M
Shs Float118.90M
Short Float6.73%
Short Ratio4.53
Short Interest8.00M
52W High5.45 -6.97%
52W Low1.35 275.56%
Volatility8.47% 7.48%
ATR (14)0.36
RSI (14)53.98
Beta0.60
Rel Volume0.35
Avg Volume1.77M
Volume96,702

Performance

Perf Week-2.12%
Perf Month7.87%
Perf Quarter47.81%
Perf Half Y152.24%
Perf YTD174.05%
Perf Year214.91%
Perf 3Y19.58%
Perf 5Y-49.15%
Perf 10Y-
Recom1.00
Target Price8.21
Prev Close5.10
Price5.07
Change %-0.59%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Nov 29, 2023InitiatedRRBC Capital MktsOutperform$6+18.3%
Apr 21, 2023InitiatedTThe Benchmark CompanyBuy$8+57.8%
Apr 13, 2023InitiatedCCraig HallumBuy$10+97.2%
Feb 22, 2023InitiatedCCowenOutperform$10+97.2%
Feb 13, 2023InitiatedHH.C. WainwrightBuy$11+117.0%
Dec 20, 2022InitiatedTTruistBuy$10+97.2%
Dec 16, 2022InitiatedCCredit SuisseOutperform$13+156.4%
Nov 29, 2022InitiatedSSVB LeerinkOutperform$6+18.3%
Nov 28, 2022InitiatedSStifelBuy$12+136.7%

Peers

Mkt cap
TickerCompanyMkt cap
ABCLAbCellera Biologics Inc4.07B
ABSIAbsci Corp1.72B
XNCRXencor Inc2.98B
LGNDLigand Pharmaceuticals Inc6.34B
GENBGenerate Biomedicines Inc1.75B
HYFTMindWalk Holdings Corp48.76M
DNAGinkgo Bioworks Holdings Inc793.09M
TWSTTwist Bioscience Corp9.05B
ADAGAdagene Inc ADR149.72M
HALOHalozyme Therapeutics Inc11.46B

Insider trading

latest 14 of 32
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GUSTAFSON KURT AOfficerApr 07 '26Proposed Sale1.496,91310,266Apr 07 08:33 PM
FOEHR MATTHEW WPresident and CEOApr 07 '26Option Exercise0.0036,45904,439,736Apr 07 08:26 PM
FOEHR MATTHEW WPresident and CEOApr 07 '26Sale1.4919,24428,6744,420,492Apr 07 08:26 PM
FOEHR MATTHEW WOfficerApr 07 '26Proposed Sale1.4919,24428,577Apr 07 08:25 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 07 '26Option Exercise0.0013,5420268,396Apr 07 08:25 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 07 '26Sale1.496,91310,300261,483Apr 07 08:25 PM
Berkman Charles SChief Legal OfficerApr 07 '26Option Exercise0.0013,5420406,242Apr 07 08:23 PM
Berkman Charles SChief Legal OfficerApr 07 '26Sale1.497,15710,664399,085Apr 07 08:23 PM
Berkman Charles SOfficerApr 07 '26Proposed Sale1.497,15710,628Apr 07 08:12 PM
Berkman Charles SChief Legal OfficerFeb 18 '26Option Exercise0.0018,7500402,373Feb 18 06:36 PM
Berkman Charles SChief Legal OfficerFeb 18 '26Sale1.719,67316,541392,700Feb 18 06:36 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOFeb 18 '26Option Exercise0.0018,7500278,152Feb 18 06:35 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOFeb 18 '26Sale1.719,30115,905268,851Feb 18 06:35 PM
FOEHR MATTHEW WPresident and CEOFeb 18 '26Sale1.7130,84352,7424,403,277Feb 18 06:34 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

News

latest 14 of 206
  • OmniAb Matches On EPS, Beats On Revenue, And Lifts Its Cash Outlook As Q3 Exposes The Lumpiness Of A Milestone-Driven Model (Earnings Whispers)
  • OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights (Business Wire)
  • OmniAb to Participate in Upcoming Investor Conferences in November (Business Wire) +7.59%
  • OmniAb Faces Quieter Milestone Quarter After A Doubling Stock And Three Guidance Raises (Earnings Whispers)
  • OmniAb to Report Third Quarter 2026 Financial Results on October 30 (Business Wire)
  • Loading…
  • OmniAb Highlights Partner Pipeline, xPloration Plans and Outlook, and Introduces the OmniTides Platform at Investor & Analyst Day (Business Wire) -11.59%
  • OmniAb to Host Investor & Analyst Day on October 6, 2026 (Business Wire) +10.07%
  • VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology (NewMediaWire)
  • OmniAb to Participate in Upcoming Investor Conferences (Business Wire)
  • OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook (GuruFocus.com) +13.02%
  • OmniAb lifts 2026 cash outlook following licensing momentum (InvestorsHub)
  • OmniAb Raises 2026 Financial Guidance (Business Wire)
  • OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-30-0.120-0.127-0.1203.993.497
2026Q22026-08-06-0.050-0.120-0.04613.424.697
2026Q12026-05-07-0.060-0.104-0.06014.435.607
2025Q42026-03-04-0.110-0.088-0.1118.389.007
2025Q32025-11-04-0.140-0.138-0.1442.244.397
2025Q22025-08-06-0.150-0.149-0.1503.905.338
2025Q12025-05-08-0.170-0.164-0.1724.154.498
2024Q42025-03-18-0.120-0.101-0.12510.8010.138
2024Q32024-11-12-0.160-0.138-0.1604.178.418
2024Q22024-08-08-0.130-0.171-0.1347.605.768
2024Q12024-05-09-0.190-0.161-0.1883.805.878
2023Q42024-03-20-0.140-0.143-0.1404.827.468
2023Q32023-11-09-0.160-0.138-0.1585.4810.336
2023Q22023-08-10-0.150-0.120-0.1486.9511.917
2023Q12023-05-11-0.060-0.031-0.06216.9218.987
2022Q42023-03-300.0700.0500.07335.3528.023

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-0.260-0.373-0.26259.0851.73
2023FY-0.510-0.494-0.50834.1637.85
2024FY-0.610-0.594-0.60626.3925.75
2025FY-0.570-0.541-0.57018.6719.25
2026FY--0.346--36.93
2027FY--0.255--46.99
2028FY--0.075--73.33
2029FY-0.123--106.04
2030FY-0.265--126.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-307705.203.706.56
2026Q4S2026-10-217103.853.004.94
2026Q4S2026-10-067163.853.004.94
2026Q4S2026-08-147163.843.004.94
2026Q4S2026-08-077073.803.004.94
2026Q4S2026-07-287006.454.699.68
2026Q4S2026-07-227016.454.699.68
2026Q4S2026-05-147076.454.699.68
2026Q4S2026-05-087066.734.699.68
2026Q4S2026-04-157219.307.1114.46
2026Q4S2026-03-057219.397.7114.46
2026Q4S2026-01-193009.078.1010.91
2026Q4S2026-01-183109.078.1010.91
2026Q4S2025-11-113119.078.1010.91

Estimate history

EPS, annual-0.327-0.262-0.508-0.606-0.57-0.3382
Period20212022202320242025TTM
EPS, quarterly-0.16-0.125-0.172-0.15-0.144-0.111-0.06-0.046-0.122
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual34.74859.07734.16426.39118.66640.21
Period20212022202320242025TTM
Sales, quarterly4.17210.8044.1543.8972.2398.37614.42713.4153.993
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual115.218115.218116.859121.599144.308145.856
Period20212022202320242025MRQ
Shares, quarterly120.223121.599122.135122.701143.955144.308144.784145.39145.856
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue40.2118.6726.3934.1659.0834.75
Cost of Goods Sold Incl. D&A24.2922.0619.6819.5016.2514.97
Gross Profit15.92-3.396.7114.6742.8319.78
Selling, General and Administrative Excl. Other62.0668.1379.6783.8970.0754.18
Research and Development42.6947.7555.1156.5248.3639.23
Other Operating Expense0.310.000.000.000.000.00
Operating Income-46.44-71.52-72.97-69.23-27.24-34.40
Interest Expense0.000.000.000.000.000.01
Unusual Expense-0.990.331.350.19-0.591.21
Net Income Before Taxes-43.88-66.29-71.41-64.36-26.06-34.35
Income Taxes-0.41-1.51-9.38-13.74-3.73-7.31
Consolidated Net Income-43.47-64.78-62.03-50.62-22.33-27.04
Net Income From Continuing Operations-43.47-64.78-62.03-50.62-22.33-27.04
Net Income-43.47-64.78-62.03-50.62-22.33-27.04
EPS (Recurring)-0.34-0.57-0.60-0.51-0.27-0.32
EPS (Basic, Before Extraordinaries)-0.34-0.57-0.61-0.51-0.26-0.33
EPS (Diluted)-0.34-0.57-0.61-0.51-0.26-0.33
EBITDA-23.10-49.76-53.28-49.73-10.99-19.43
Non-Operating Income (Expense)1.575.552.915.060.591.27
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense10.4012.5016.9819.6114.4711.00
Price To Sales Ratio15.9511.2613.7318.005.2023.73
Gross Margin39.60-18.1725.4242.9372.4956.92
Operating Margin-115.50-383.15-276.48-202.63-46.11-99.00
Net Margin-108.11-347.04-235.05-148.16-37.80-77.82
Shares Outstanding145.86144.31121.60116.86115.22115.22
Market Capitalization743.89743.89428.39717.15413.36413.36

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue3.9913.4114.438.382.243.904.1510.80
Cost of Goods Sold Incl. D&A4.524.837.237.724.684.914.744.91
Gross Profit-0.528.597.200.66-2.44-1.01-0.595.90
Selling, General and Administrative Excl. Other15.6415.0715.0716.2715.7317.1319.0019.12
Research and Development9.559.599.6413.9110.3810.8612.6013.31
Other Operating Expense0.000.000.270.03-0.01-1.310.090.00
Operating Income-16.17-6.49-8.15-15.64-18.16-16.83-19.68-13.22
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.20-0.60-0.320.12-0.02-0.61-0.832.56
Net Income Before Taxes-15.86-6.21-7.26-14.55-17.69-15.76-18.31-15.22
Income Taxes-0.13-0.350.44-0.37-1.160.12-0.11-2.15
Consolidated Net Income-15.73-5.86-7.71-14.18-16.52-15.88-18.20-13.07
Net Income From Continuing Operations-15.73-5.86-7.71-14.18-16.52-15.88-18.20-13.07
Net Income-15.73-5.86-7.71-14.18-16.52-15.88-18.20-13.07
EPS (Recurring)-0.12-0.05-0.06-0.11-0.14-0.15-0.18-0.11
EPS (Basic, Before Extraordinaries)-0.12-0.05-0.06-0.11-0.14-0.15-0.17-0.12
EPS (Diluted)-0.12-0.05-0.06-0.11-0.14-0.15-0.17-0.12
EBITDA-11.96-2.27-0.94-7.93-13.51-12.18-14.94-8.31
Non-Operating Income (Expense)0.11-0.330.561.220.450.460.540.56
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.422.502.642.853.133.253.274.04
Price To Sales Ratio15.958.246.9612.678.708.029.4814.06
Gross Margin-13.1064.0149.897.88-109.20-26.02-14.1854.59
Operating Margin-404.86-48.36-56.48-186.75-811.26-431.82-473.71-122.37
Net Margin-393.89-43.67-53.42-169.28-738.05-407.36-438.13-120.96
Shares Outstanding145.86145.39144.78144.31143.96122.70122.13121.60
Market Capitalization743.89356.63227.31266.32230.33210.56290.43428.39

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments54.0259.4386.9888.270.00
Short Term Receivables7.395.273.8430.2921.14
Inventories0.820.000.000.000.00
Other Current Assets3.103.434.076.391.41
Total Current Assets65.3468.1494.90124.9522.54
Net Property, Plant & Equipment24.9733.2838.1341.4620.13
Total Investments and Advances0.560.560.560.450.00
Intangible Assets209.13222.04239.45251.22260.30
Deferred Tax Assets32.0033.0726.7618.5316.94
Other Assets0.911.542.193.131.50
Total Assets332.91358.63401.99439.74321.41
Short Term Debt Incl. Current Port. of LT Debt3.883.783.491.780.58
Accounts Payable1.882.304.412.972.92
Income Tax Payable--0.003.480.00
Other Current Liabilities10.509.0115.2217.7917.07
Total Current Liabilities16.2515.0923.1226.0220.58
Long Term Debt16.4519.3822.0724.0213.27
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities32.7835.3838.1139.8738.90
Other Liabilities0.391.164.098.4614.35
Total Liabilities65.8971.0187.4098.3787.10
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity267.03287.62314.58341.37234.31
Total Shareholders Equity267.03287.62314.58341.37234.31
Accumulated Minority Interest0.000.000.000.000.00
Total Equity267.03287.62314.58341.37234.31
Total Liabilities & Stockholders Equity332.91358.63401.99439.74321.41
Book Value Per Share1.852.372.692.962.03
Tangible Book Value Per Share0.400.540.640.78-0.23
Full-Time Employees89114106957
Price to Book Ratio2.991.462.210.460.46
Return on Assets-18.73-16.31-12.03-6.60-
Return on Equity-23.36-20.60-15.43-7.84-
Return on Invested Capital-22.85-20.21-15.04-6.11-10.92
Quick Ratio3.974.524.114.801.10
Current Ratio4.024.524.114.801.10

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-43.47-64.78-62.03-50.62-22.33-27.04
Depreciation23.3521.7519.6819.5018.2516.25
Other Funds (Non Cash)13.0413.0521.9021.1417.7515.07
Funds from Operations-7.49-31.50-29.49-22.527.25-3.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital10.16-4.95-10.1724.87-10.83-2.63
Cash from Operating Activities2.67-36.45-39.662.35-3.59-5.67
Capital Expenditures-0.29-0.56-1.88-1.64-17.17-4.07
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-9.674.0340.16-12.29-54.701.26
Purchase of Investments-57.32-46.86-40.29-112.62-54.770.00
Sale Or Maturity of Investments47.6450.8980.45100.320.071.26
Other Uses0.000.00-0.40-4.44-1.44-1.22
Other Sources0.003.000.000.000.000.00
Cash from Investing Activities-9.966.4737.88-18.38-73.31-4.03
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock1.9028.3614.050.7396.680.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.9028.3614.050.7396.680.00
Proceedsfrom Stock Options1.9028.3614.050.7396.680.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.26-0.45-1.03-1.6214.069.70
Other Financing Activities Uses-0.26-0.45-1.03-1.62-2.02-1.05
Cash from Financing Activities1.6427.9113.02-0.89110.749.70
Net Change in Cash-5.65-2.0711.24-16.9233.840.00
Free Cash Flow2.38-37.02-41.540.70-20.75-9.74
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Price to Free Cash Flow269.46--874.88--
Deferred Taxes & Investment Tax Credit--1.53-9.04-12.54-6.42-7.33

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments64.2151.9949.0754.0259.5041.62
Short Term Receivables2.5710.3312.647.393.102.71
Inventories1.071.010.920.820.000.00
Other Current Assets3.122.682.493.103.753.30
Total Current Assets70.9866.0165.1265.3466.3547.62
Net Property, Plant & Equipment21.8022.9424.0724.9729.4030.75
Total Investments and Advances0.560.560.560.560.560.56
Intangible Assets196.99200.05203.10209.13212.36215.58
Deferred Tax Assets---32.00--
Other Assets0.580.700.800.911.031.17
Total Assets290.92290.26293.65332.91309.69295.67
Short Term Debt Incl. Current Port. of LT Debt4.003.973.943.883.863.84
Accounts Payable1.412.091.651.881.911.98
Other Current Liabilities11.447.707.9710.507.516.82
Total Current Liabilities16.8513.7613.5716.2513.2812.64
Long Term Debt14.1314.9415.7316.4517.2117.94
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.760.881.2332.781.172.33
Other Liabilities10.020.400.480.390.590.71
Total Liabilities41.7629.9831.0065.8932.2533.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity249.16260.27262.65267.03277.44262.06
Total Shareholders Equity249.16260.27262.65267.03277.44262.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity249.16260.27262.65267.03277.44262.06
Total Liabilities & Stockholders Equity290.92290.26293.65332.91309.69295.67
Book Value Per Share1.711.791.811.851.932.14
Tangible Book Value Per Share0.360.410.410.400.450.38
Full-Time Employees---89--
Price to Book Ratio2.991.360.850.960.750.78
Return on Assets-14.48-15.11-18.10-18.73-19.86-20.07
Return on Equity-16.51-16.95-20.25-23.36-22.37-22.84
Return on Invested Capital-5.97-2.13-2.77-5.00-5.61-5.67
Quick Ratio4.154.724.733.975.003.77
Current Ratio4.214.804.804.025.003.77

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-15.73-5.86-7.71-14.18-16.52-15.88
Depreciation4.214.227.217.714.664.65
Other Funds (Non Cash)3.013.062.884.093.802.06
Funds from Operations-8.631.072.83-2.76-9.23-9.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital19.211.61-7.74-2.92-0.533.90
Cash from Operating Activities10.572.68-4.91-5.67-9.76-5.15
Capital Expenditures0.00-0.11-0.17-0.01-0.18-0.17
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-13.49-7.518.602.72-7.489.46
Purchase of Investments-16.03-23.61-9.40-8.28-19.98-8.34
Sale Or Maturity of Investments2.5416.1018.0011.0012.5017.80
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.003.00
Cash from Investing Activities-13.49-7.628.442.71-7.6712.30
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.610.350.00-0.0528.130.24
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.610.350.00-0.0528.130.24
Proceedsfrom Stock Options1.610.350.00-0.0528.130.24
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.15-0.110.000.00-0.450.00
Other Financing Activities Uses-0.15-0.110.000.00-0.450.00
Cash from Financing Activities1.460.230.00-0.0527.680.24
Net Change in Cash-1.45-4.713.52-3.0110.267.39
Free Cash Flow10.572.57-5.08-5.68-9.95-5.31
Price to Free Cash Flow269.46-----

Revenue breakdown

License And Milestone2024: 13.87M 2025: 9.77M
Royalty2024: 576.00K 2025: 878.00K
Service2024: 11.95M 2025: 7.26M
xPloration2025: 754.00K
United States2024: 26.39M 2025: 18.67M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.73%8.0M118.9M1.68M
2026-10-157.21%8.5M118.5M1.48M
2026-09-306.92%8.2M118.5M1.37M
2026-09-156.01%7.1M118.5M1.30M
2026-08-315.05%6.0M118.4M1.09M
2026-08-145.27%6.2M118.4M651.44K
2026-07-315.08%6.0M118.1M685.35K
2026-07-154.98%5.9M118.1M747.42K
2026-06-304.03%4.8M118.1M726.63K
2026-06-153.98%4.7M118.1M651.53K
2026-05-293.96%4.7M118.1M635.26K
2026-05-154.17%4.9M118.1M544.95K
2026-04-304.45%5.3M118.0M406.51K
2026-04-154.63%5.5M118.1M375.36K
2026-03-315.04%5.9M117.9M339.28K
2026-03-134.78%5.6M117.9M409.08K
2026-02-274.91%5.8M117.9M435.09K
2026-02-134.94%5.8M117.2M496.68K
2026-01-305.35%5.8M109.0M517.61K
2026-01-155.43%5.9M109.1M528.28K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.403.201.957.3611.000.000.958-0.0120.001
call5.000.150.500.321.4604122.000.570-0.0230.003
call7.500.000.050.051.5933520.000.090-0.0110.001
put2.500.000.050.002.9210.000.00-0.042-0.0110.001
put5.000.000.350.451.2211530.00-0.429-0.0240.003
put7.501.153.702.856.1120.000.00-0.910-0.0110.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-024Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-10-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-308-KCurrent report2026-10-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-07-133Initial statement of beneficial ownership of securities2026-07-13SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-17SEC
2026-04-214Statement of changes in beneficial ownership of securities2026-04-21SEC
2026-04-214Statement of changes in beneficial ownership of securities2026-04-21SEC
2026-04-07144Filing for proposed sale of securities under Rule 144.SEC
2026-04-07144Filing for proposed sale of securities under Rule 144.SEC
2026-04-07144Filing for proposed sale of securities under Rule 144.SEC
2026-04-074Statement of changes in beneficial ownership of securities2026-04-07SEC
2026-04-074Statement of changes in beneficial ownership of securities2026-04-07SEC
2026-04-074Statement of changes in beneficial ownership of securities2026-04-07SEC
2026-03-0410-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040049.64K3
2026-030000
2026-0200143.96K6
2026-010000
2025-120089.44K3
2025-11107.71K200

Institutional holders

Manager% owned
Whitefort Capital Management, LP7.07%
BlackRock, Inc.6.14%
NOMURA HOLDINGS INC3.47%
CADIAN CAPITAL MANAGEMENT, LP2.91%
VANGUARD CAPITAL MANAGEMENT LLC2.66%
GEODE CAPITAL MANAGEMENT, LLC1.94%
RICE HALL JAMES & ASSOCIATES, LLC1.80%
STATE STREET CORP1.47%
PRIVATE MANAGEMENT GROUP INC1.38%
DIMENSIONAL FUND ADVISORS LP0.85%

Funds

Fund% owned
iShares Russell 2000 ETF1.93%
Fidelity Small Cap Index Fund0.83%
Fidelity Extended Market Index Fund0.41%
Schwab U.S. Small-Cap ETF0.38%
iShares Micro-Cap ETF0.25%
Janus Henderson Triton Fund0.23%
VANGUARD HEALTH CARE INDEX FUND0.17%
Clearwater Select Equity Fund0.16%
Fidelity Total Market Index Fund0.16%
Fidelity Enhanced Small Cap Core ETF0.13%

OakChart. OABI. Cached 15 minutes.